Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

NCT03373708 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Chemotherapy
Endocrine Breast Diseases

Interventions

DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Docetaxel
DRUG: Goserelin acetate
DRUG: Tamoxifen
DRUG: Letrozole

Sponsor

Zhiyong Yu